Edwards Lifesciences CORP Form 4 insider transactions

Daniel J. Lippis, CVP of JAPAC at Edwards Lifesciences, reports the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 trading plan.

Scott Ullem, CFO of Edwards Lifesciences, reports the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 trading plan.

Bernard J. Zovighian, CEO of Edwards Lifesciences, amended a previous Form 4 filing to accurately reflect indirect beneficial ownership of common stock held within the company's 401(k) plan.

Donald E. Bobo Jr., a CVP at Edwards Lifesciences, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

CEO Bernard Zovighian sold 8,617 shares of Edwards Lifesciences Corp. common stock at $87.68 per share on May 30, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences' CFO, Scott Ullem, exercised stock options and sold shares on May 21, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Robert W.A. Sellers, SVP, Corporate Controller at Edwards Lifesciences, reported the disposal of 229 shares of common stock at a price of $86.72 on May 11, 2024.

Catherine M. Szyman, CVP at Edwards Lifesciences, disposed of 827 shares of common stock on May 11, 2024, to cover tax obligations.

Larry L. Wood, Global President TAVR & Surg at Edwards Lifesciences, reports disposition of shares to cover tax obligations.

Daniel J. Lippis, CVP of JAPAC at Edwards Lifesciences, reported the disposal of 377 shares of common stock to cover tax obligations.

Jean-Luc M Lemercier, a CVP at Edwards Lifesciences, reported a transaction involving common stock on May 11, 2024.

Daveen Chopra, CVP of TMTT at Edwards Lifesciences, reported the disposal of 821 shares of common stock on May 11, 2024.

Donald E. Bobo Jr., CVP of Strategy/Corporate Development at Edwards Lifesciences, executed transactions involving company stock, including the sale of 5,000 shares, under a pre-arranged 10b5-1 trading plan.

CEO Bernard J. Zovighian of Edwards Lifesciences Corp. reported the disposal of 2,854 shares of common stock to cover tax obligations.

CFO of Edwards Lifesciences, Scott B. Ullem, reports changes in beneficial ownership of company stock following a transaction on May 11, 2024.

Director Steven R. Loranger reports the acquisition of common stock and restricted stock units in Edwards Lifesciences Corp.

Nicholas J. Valeriani, a director at Edwards Lifesciences, acquired 4,818 shares of common stock through a restricted stock unit grant.

Director Ramona Sequeira reports acquisition of 3,055 restricted stock units in Edwards Lifesciences Corp.

Director Paul A. Laviolette reports the acquisition of 3,055 shares of Edwards Lifesciences Corp. common stock through a restricted stock unit grant.

Leslie Stone Heisz, a director at Edwards Lifesciences, reported the acquisition of 3,055 restricted stock units on May 8, 2024.

Director Kieran Gallahue reports the acquisition of restricted stock units and a restricted stock award from Edwards Lifesciences on May 8, 2024.

Leslie C. Davis, a director at Edwards Lifesciences, reported the acquisition of 3,055 restricted stock units on May 8, 2024.

Donald E. Bobo Jr., CVP of Strategy/Corporate Development at Edwards Lifesciences, reports acquisition of stock options and restricted stock units, as well as disposition of shares to cover tax obligations.

Daniel J. Lippis, CVP of JAPAC at Edwards Lifesciences, reports acquisition and disposal of company stock and derivative securities.

Daveen Chopra, CVP of TMTT at Edwards Lifesciences, reports acquisition and disposal of company stock and derivative securities.

Jean-Luc Lemercier, CVP of EMEACLA and JAPAC at Edwards Lifesciences, reports the acquisition of stock and option awards.

Larry L. Wood, Global President of TAVR & Surgical at Edwards Lifesciences, reports the acquisition of stock options and restricted stock units, as well as the disposition of shares to cover tax obligations.

CEO Bernard J. Zovighian reports the acquisition of restricted stock units and stock options, along with a disposition of shares to cover tax obligations.

Scott Ullem, CFO of Edwards Lifesciences, reports the acquisition of stock options and restricted stock units (RSUs) and the disposition of shares to cover tax obligations.

Robert W.A. Sellers, SVP, Corporate Controller at Edwards Lifesciences, reports acquisition and disposal of common stock and stock options.